VIVUS (STU:VIU1) Long-Term Debt : €53.31 Mil (As of Mar. 2020)

View and export this data going back to . Start your Free Trial

What is VIVUS Long-Term Debt?

VIVUS's Long-Term Debt for the quarter that ended in Mar. 2020 was €53.31 Mil.

VIVUS's quarterly Long-Term Debt declined from Sep. 2019 (€53.15 Mil) to Dec. 2019 (€52.85 Mil) but then increased from Dec. 2019 (€52.85 Mil) to Mar. 2020 (€53.31 Mil).

VIVUS's annual Long-Term Debt increased from Dec. 2017 (€194.80 Mil) to Dec. 2018 (€258.82 Mil) but then declined from Dec. 2018 (€258.82 Mil) to Dec. 2019 (€52.85 Mil).

VIVUS Long-Term Debt Historical Data

The historical data trend for VIVUS's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

VIVUS Long-Term Debt Chart

VIVUS Annual Data

Trend

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Long-Term Debt

Get a 7-Day Free Trial

199.24

220.51

194.80

258.82

52.85

VIVUS Quarterly Data
	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20
Long-Term Debt	Get a 7-Day Free Trial															259.66	94.70	53.15	52.85	53.31

VIVUS (STU:VIU1) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

VIVUS Long-Term Debt Related Terms

Thank you for viewing the detailed overview of VIVUS's Long-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

VIVUS (STU:VIU1) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » VIVUS Inc (STU:VIU1) » Definitions » Long-Term Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

900 East Hamilton Avenue, Suite 550, Campbell, CA, USA, 95008

Website

http://www.vivus.com

VIVUS Inc is a US-based biopharmaceutical company engaged in developing and commercializing, next-generation therapies to address unmet medical needs in human health. Its commercial products include Qsymia, an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index; PANCREAZE which is a is a pancreatic enzyme preparation consisting of pancrelipase, an extract derived from porcine pancreatic glands, as well as other enzyme classes and STENDRA/SPEDRA, which is an oral phosphodiesterase type 5 inhibitor for the treatment of erectile dysfunction.

VIVUS (STU:VIU1) Headlines

No Headlines